About Rhelixa-inc

The startup develops epigenome analysis technology that enhances the precision and efficiency of life science research by providing tailored consulting on experimental design and biological interpretation. Their solutions enable clients to streamline research and development processes, ultimately improving the accuracy of their scientific outcomes.

```xml <problem> Life science research requires precise and efficient epigenome analysis, but researchers often face challenges in experimental design and biological interpretation, leading to inefficiencies in R&D processes. Analyzing omics information, such as genomics, epigenomics, transcriptomics, and metagenomics, can be complex and time-consuming without specialized expertise. </problem> <solution> Rhelixa provides tailored consulting and services in epigenome analysis to enhance the precision and efficiency of life science research. By leveraging proprietary technology and know-how, Rhelixa assists clients in streamlining their research and development processes. The company decodes omics information, including genomics, epigenomics, transcriptomics, and metagenomics, to improve the accuracy of scientific outcomes. Rhelixa's mission is to accelerate the advancement of life science research through meticulous support and the integration of cutting-edge technologies aligned with client objectives. </solution> <features> - Next-generation sequencing data acquisition and analysis - Omics research support cloud tool RIAS® - Biological age testing using EpiClock® - IPA pathway analysis - Consulting services for experimental design - Biological interpretation of omics data </features> <target_audience> The primary customers are researchers and organizations in the life science, medical, and pharmaceutical industries seeking to improve their research and development outcomes through advanced epigenome analysis. </target_audience> ```

What does Rhelixa-inc do?

Where is Rhelixa-inc located?

Rhelixa-inc is based in Tokyo, Japan.

Location

Tokyo, Japan

Employees

10 employees

Major Investors

Joyo Bank, Japan Finance Corporation

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Rhelixa-inc

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

rhelixa.com 10+

Crunchbase

Tokyo, Japan

Funding

Major Investors

Joyo Bank, Japan Finance Corporation

Team (10+)

No team information available.

Company Description

Problem

Life science research requires precise and efficient epigenome analysis, but researchers often face challenges in experimental design and biological interpretation, leading to inefficiencies in R&D processes. Analyzing omics information, such as genomics, epigenomics, transcriptomics, and metagenomics, can be complex and time-consuming without specialized expertise.

Solution

Rhelixa provides tailored consulting and services in epigenome analysis to enhance the precision and efficiency of life science research. By leveraging proprietary technology and know-how, Rhelixa assists clients in streamlining their research and development processes. The company decodes omics information, including genomics, epigenomics, transcriptomics, and metagenomics, to improve the accuracy of scientific outcomes. Rhelixa's mission is to accelerate the advancement of life science research through meticulous support and the integration of cutting-edge technologies aligned with client objectives.

Features

Next-generation sequencing data acquisition and analysis

Omics research support cloud tool RIAS®

Biological age testing using EpiClock®

IPA pathway analysis

Consulting services for experimental design

Biological interpretation of omics data

Target Audience

The primary customers are researchers and organizations in the life science, medical, and pharmaceutical industries seeking to improve their research and development outcomes through advanced epigenome analysis.